23andMe teams with Pfizer to study bowel disease

Pfizer is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

See original post by San Jose Mercury News